The Lancet Oncology: Nationwide study sets benchmarks for 30-day mortality following chemotherapy for breast and lung cancer in England

August 30, 2016

For the first time, national data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy have been collected and analysed in order to help clinical teams review and improve patient care, and identify groups of patients who may have additional needs.

The study, published in The Lancet Oncology is the first time this type of data has been collected at a national level in any country. It identifies factors such as age and general well-being that affect 30-day mortality, as well as NHS trusts with higher than expected rates of mortality.

The study includes all breast and lung cancer patients who received one or more cycles of systemic anti-cancer therapy (SACT) in NHS trusts in England in 2014 - a total of 28364 women with breast cancer and 15045 men and women with lung cancer. Data were gathered from Public Health England's SACT dataset.

In this study, 30-day mortality was 8.47% for patients with lung cancer (1274/15045) and 2.47% for patients with breast cancer (700/28364). 30-day mortality was higher for patients receiving palliative treatment (10% for lung cancer 1061/10587; 7.48% for breast cancer 569/7602), compared to patients receiving curative treatment (2.88% for lung cancer 70/2429; 0.26% for breast cancer 41/15626) (table 2).

The use of SACT has increased substantially in the past 30 years. Whereas it was previously only used to treat a small number of cancer types, it is now used routinely in many patients with common cancers. SACT can be given with the aim of improving long-term survival, either alone or in combination with surgery or radiotherapy, or for palliative purposes, to improve the quality of life for patients with advanced incurable cancers for as long as possible by controlling cancer growth and providing symptom relief.

Patients dying within 30 days after beginning systemic treatment are unlikely to have gained the survival or palliative benefits of the treatment, and because of the associated side-effects (eg, the risk of neutropenic sepsis) may be more likely to have suffered harm. It may therefore be a useful indicator of avoidable harm, but so far data on how it is used have been limited.

The study also examined a number of risk factors for 30-day mortality for all patients that could be included in those analyses - 23228 women with breast cancer and 9634 men and women with non-small cell lung cancer.

30-day mortality was higher for patients receiving their first reported SACT treatment - whether curative or palliative - compared to those who had already received one or more cycles of SACT (tables 4-7). 30-day mortality increased with age for both patients with breast or lung cancer treated with curative intent, and decreased with age for patients receiving palliative SACT. The authors say this may be because older patients may favour other forms of palliative care over SACTs, or because younger patients might have more aggressive forms of cancer.

30-day mortality was also generally higher for patients with worse general health, compared to those in better health. For example, 3% (13/480) of patients with non-small cell lung cancer (NSCLC) treated with curative intent who had a performance status (PS) of 0 died within 30-days; compared to 5% (4/88) with a PS 2-4 (table 6). The authors say this is possibly because patients in poorer general health may be less able to tolerate the negative side-effects of SACT, suggesting that care is required when advising chemotherapy in this patient group.

"Simply reducing doses of or avoiding SACT altogether would reduce or eliminate instances of treatment-related early mortality, but at the cost of some patients being denied effective SACT and hence the survival and palliation benefits. In order to maximise the benefits of systemic treatment, it is important to gain a detailed understanding of how many different factors affecting patients are linked to the increased risk of early mortality." says co-author Professor David Dodwell, Institute of Oncology, St James Hospital, Leeds, UK. "Patient choice is an important factor in decisions about treatment and the factors we have identified may provide a focus of discussions about treatment between patients and their clinicians to allow better informed decisions." [1]

Additionally, several trusts were found to have higher rates of 30-day mortality after SACT than expected, including seven for curative breast cancer, four for palliative breast cancer, five for curative NSCLC and seven for palliative NSCLC (figures 2-5). The authors say there may be a number of reasons why trusts are identified as outliers including poor data management, poor clinical care or decision making, and have written to all trusts to inform them on their 30-day mortality status, encouraging them to review their practices.

"This important study uses real clinical data, rather than trial data, from patients across the NHS to examine the quality of care and clinical decision making. Public Health England's National Cancer Registration and Analysis Service will work with all trusts to help them understand the findings and the implications for their data collection and care," says Dr Jem Rashbass, co-author and Cancer Lead at Public Health England, UK. [1]

The authors note that although they identified several factors affecting 30-day mortality risk, the dataset only included patients who received SACT, so no information is available about whether patients would have had better outcomes without SACT.

Writing in a linked Comment, Professor David Cameron, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, says: "This is a very welcome report, and gives for the first time a national picture of factors that affect the likelihood of death, and complements the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report's focus on the process of care." He adds that "despite this initiative to collate national data for cancer chemotherapy, there were significant gaps and deficiencies in the national dataset. To someone who has worked in the UK National Health Service their whole clinical life, it remains a tragedy that we still cannot get complete national (anonymised) datasets to inform clinicians and patients and to drive real improvements in patient care. This study, despite its limitations, sets a standard for what health-care systems should achieve: to routinely record, collate, and report at a national level the negative consequences of medical interventions to improve the quality of health care."

The study was funded by Public Health England.

[1] Quotes direct from author and cannot be found in the text of the Article.


The Lancet

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to